


BioPact
Biotechnology Research • Austin, Texas, United States • 1-10 Employees
Company overview
| Headquarters | 12310 Trail Driver Street, Austin, Texas 78737, US |
| Phone number | +18005617087 |
| Website | |
| NAICS | 541714 |
| Keywords | Drug Delivery, Nanotechnology, Rnai, Genetic Engineering, Gene Delivery, Protein Delivery, Agricultural Bioengineering, Antibody Delivery, Cellular Delivery, Genetically Modified Organisms, Intracellular Delivery, Strain Development, Trans-Membrane Delivery |
| Founded | 2014 |
| Employees | 1-10 |
| Socials |
Key Contact at BioPact
Aaron Foote
Director Of Technology Development / Principal Investigator
BioPact Email Formats
BioPact uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@bio-pact.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@bio-pact.com | 100% |
About BioPact
Biopact is a Molecular Rebar Design Company focusing on nanoscale biomaterials company developing the MGMR intracellular delivery vehicle. MGMR is a cellular-engineering tool for biomanufacturing and agricultural processes which value efficient delivery of RNAs, peptides, and genetic materials. MGMR is a highly-efficient intracellular delivery vehicle, consisting of a stabile dispersion of hollow, nanoscale tubules approximately 1/10,000th the width of a human hair. The high aspect-ratio, nanoscale profile of MGMR allows it to readily penetrate cells without compromising membrane integrity or inducing cytotoxicity. Its high surface-to-volume ratio and tunable surface chemistry allow it to readily transport both small and large-molecular payloads into the cytoplasm, including growth factors, oligonucleotides, proteins and gene-editing complexes. Biopact has evaluated the cytotoxicity profile of MGMR across multiple cell-lines and investigated safety and efficacy in murine biodistribution and clearance models. Our in vivo studies demonstrate that MGMR is biologically-inert, well-tolerated and rapidly cleared from non-targeted tissues. In a murine therapeutic model, MGMR loaded with doxorubicin (Dox) demonstrated a remarkable capability to rapidly concentrate drug in targeted tissues and extend half-life of its molecular cargo. Promising assessments of intracellular delivery performance in different eukaryotic cell-types suggest the potential for developing MGMR as a biomolecular delivery vehicle for various expression platforms and cell-factories of interest to agricultural and industrial applications, including mammalian cell-lines, yeasts, bacteria and plants. Robust cellular uptake observed with MGMR offers the potential to deliver molecular payloads to difficult-to-penetrate cell-types or those acutely sensitive to detergents and other conventional methods for transmembrane delivery.
BioPact revenue & valuation
| Annual revenue | $5,199,004 |
| Revenue per employee | $1,300,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $16,700,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
BioPact has never raised funding before.
BioPact Tech Stack
Discover the technologies and tools that power BioPact's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
Tag managers
Hosting
Reverse proxies
JavaScript libraries
Programming languages
WordPress plugins
Miscellaneous
JavaScript libraries
Blogs
UI frameworks
Frequently asked questions
4.8
40,000 users



